Press releases
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo and Sobi agree to advance feasibility study with AmorphOX
More ▼
Key statistics
As of last trade Orexo AB (0H19:LSE) traded at 16.98, -12.45% below its 52-week high of 19.40, set on Jul 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.71 |
---|---|
High | -- |
Low | -- |
Bid | 16.04 |
Offer | 17.72 |
Previous close | 16.98 |
Average volume | 0.11 |
---|---|
Shares outstanding | 34.71m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 597.02m SEK |
EPS (TTM) | -3.73 SEK |
Data delayed at least 20 minutes, as of Apr 26 2024 19:05 BST.
More ▼